Data Projects That Nationwide Cannabis Retail Sales to Surpass USD 20 Billion by 2022

Wednesday, July 11, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+ News Commentary

NEW YORK, July 11, 2018 /PRNewswire/ --

According to a research report

provided by Marijuana Business Daily, cannabis retail sales continue to grow year-over-year as new markets appear and more states legalize medical and recreational cannabis products. Sales in 2018 are expected to increase by approximately 50% compared
to 2017. Sales value is on track to reach USD 8 Billion - USD 10 Billion by the end of this year. The report also indicates that by 2022, annual retail cannabis sales in the United States could surpass the USD 20 Billion mark, a 200% increase from 2017. As for the economic impact that the growing industry is set to have, the data predicts an estimated USD 28 Billion - USD 34 Billion of economic impact in 2018. Crop Infrastructure Corp. (OTC: CRXPF), Auxly Cannabis Group Inc. (OTC: CBWTF), United Cannabis Corporation (OTC: CNAB), GB Sciences Inc. (OTC: GBLX), mCig Inc. (OTC: MCIG)

On June 19th, 2018, Canada passed a nationwide legalization of recreational cannabis usage, following Uruguay to become the second nation to do so. According to the New York Times, Tony Dean, the Senator who sponsored the bill in the Chamber, said that, "We've just witnessed a historic vote for Canada, the end of 90 years of prohibition. Now we can start to tackle some of the harms of cannabis." Mr. Dean continued, "We can start to be proactive in public education. We'll see the end of criminalization and we can start addressing Canada's USD 7 Billion illegal markets."

Crop Infrastructure Corp. (OTC: CRXPF) is also listed on the Canadian Securities Exchange under the ticker (CSE: CROP). Earlier today the company announced breaking news that, its 30% owned Italy Joint Venture partner "XHemplar Italia" has planted 25 acres or 1,089,000 square feet of high CBD "Cannabis Light" in North Eastern Italy. This represents over a 100% increase on the previously announced capacity announced in press release dated June 27th 2018.

The Joint Venture's resulting high CBD "Cannabis Light" will be processed and sold into international CBD markets under white label, the venture's house name XHemplar and Crop brands Tiffany CBD and Hempire Italia. The company will also use the production to infuse its recently announced therapeutic and cosmetic product lines, licensed from The Yield Growth Corp., which transaction is now complete giving Crop exclusive rights in Italy to over 55 wellness products.

According to Arcview Market Research and its partner, BDS Analytics, government-subsidized health care spending (worldwide market at $1.3-trillion) is expected to make Europe among the fastest growing and largest medical cannabis markets in the world. Arcview expects Italy to be the second largest cannabis market in Europe by 2027 with $1.2 billion in sales.

CROP Infrastructure Director & CEO Michael Yorke states: "The company is extremely encouraged by the fast pace with which the team at XHemplar has commenced production in Italy. CROPs portfolio of cannabis infrastructure assets now includes cultivation properties in California, Washington State, Nevada, Italy and joint ventures on West Hollywood and San Bernardino dispensary applications. CROP has developed a portfolio of 15 Cannabis brands and also has US and Italian distribution rights to a line of over 55 cannabis topical products. Management will continue to aggressively pursue new world-wide opportunities and expand its portfolio of tenant growers and infrastructure assets in strategic licensed jurisdictions."

XHemplar Chairman and CROP Infrastructure VP of M&A, EMEA Andrea Castiglione states: "This is a great start for the company in Italy. We are pleased by how quickly our joint venture team has worked together to begin this initial production."

About XHemplar: Hemplar is a joint venture between CROP Infrastructure Stratto, LLC and the AnCaPa SRL of the prominent Castiglione family. This endeavor will be led locally by the CEO of XHemplar Giuseppe Castiglione who has spent the past 30 years in National and International politics roles ranging from Vice President of Sicily - with special delegation on Agriculture and Industrial development - to member of the European Parliament - where he acted as head supervisor of the European Wine Reform - to Vice Minister of Agriculture and Forestry Politics for the Italian central government in three consecutive legislatures. As an agricultural company XHemplar enjoys substantially lower tax rates with 4% VAT in Italy from which the company will greatly benefit in these early stages.

Auxly Cannabis Group Inc. (OTCQX: CBWTF) is a collective of entrepreneurs with a passion for the cannabis industry past, present and future. Recently, the Company provided the following construction development update on the joint venture with FV Pharma Inc., a wholly-owned subsidiary of FSD Pharma Inc., at the former Kraft food-production facility located in Cobourg, Ontario. The Facility hosts an initial 620,000 sq. ft. of building space, a portion of which is currently licensed for cultivation, pursuant to the Access to Cannabis for Medical Purposes Regulations and can support additional expansion capacity of approximately 3,800,000 sq. ft. on the existing property, pending completion of all phases of the project. Chuck Rifici, Chairman and Chief Executive Officer of Auxly commented, "As Canada moves towards legalization of adult-use cannabis and meaningfully expands its medical cannabis program, Auxly remains committed to cultivating quality cannabis flower at a meaningful scale. Cultivating cannabis requires a significant amount of energy in order to ensure proper growing conditions and this is one of the main contributors to overall operations costs. The technological advancements to be implemented at the facility provide us with flexibility in terms of securing a stable supply of energy while maintaining competitive operating costs relative to the rest of the industry."

United Cannabis Corporation (OTCQB: CNAB) is a biotechnology company dedicated to the development of phyto-therapeutic based products supported by patented technologies for the pharmaceutical, medical, and industrial hemp markets. The Company recently announced that the South African Patent Office has declared effective the Company's patent application based upon PCT/US2015/056635, and pursuant to the Patent Cooperation Treaty (PCT), for "Cannabis Extracts and Methods of Preparing and Using Same." The processes included in the filing are integral to the Company's branded products, including the Prana Bio Nutrient Medicinals line, and comprise the application of strain specific ratio based phytocannabinoids, cannabinoids, chemical-free extractions, and the use of cannabis derived terpenes in the medical and pharmaceutical delivery methods including capsules, sublinguals, topicals, transdermal applications, supplements, edibles, aerosol sprays, nebulizers, inhalers, aromatherapy, suppositories, and vaporization. Earnest Blackmon, United Cannabis' Chief Executive Officer, commented on the approval: "South Africa is one of many markets where medical marijuana is viewed favorably, and we look forward to establishing a strong presence there, and making our Prana products available to qualified patients across the country. As we continue to move into new markets it's important that we protect our innovations and the investment that we have made in product development, so we are very pleased that the South African Patent Office has approved our patent application."

GB Sciences Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods, as well as biopharmaceutical research and development. GB Sciences recently announced the filing of a new provisional patent application on the use of cannabis-based therapies for the manipulation of cannabis-sensitive ion channels in sensory neurons that contribute to chronic inflammatory pain conditions, peripheral neuropathy, urinary cystitis, asthma, and specific types of hearing loss. The GB Sciences drug development team believes that these new cannabis-based treatments could well herald the dawning of 'individualized medicines' from the cannabis plant by re-establishing balance in each individual patient's endocannabinoid system. "Manipulating the TRP channels in sensory neurons could provide much needed relief for patients who are suffering from chronic pain, asthma, urinary cystitis, or hearing loss," explains Dr. Andrea Small-Howard, Chief Science Officer of GB Sciences. "The ability to use specific combinations of cannabinoids and terpenoids to modulate TRP ion channels in sensory neurons could usher in the beginning of a new era of precision medicines derived from the cannabis plant."

mCig Inc. (OTC: MCIG) is a diversified company servicing the legal cannabis, hemp, and CBD markets via its lifestyle brands. The Company recently provided an update for its HEMP project and the new line of CBD products, soon to be hitting the markets. "NYAcres Project growing 40 acres of Industrial Hemp- a CBD concentrated organic variety called Cherry Wine - is on target with projections to yield 55,000 pounds of flower for production of organic CBD oil. Five fields are planted and secured on the 220-acre organic certified farm with daily maintenance and irrigation to mitigate mother nature's whims and cross pollinated with organic honey bees to strengthen conditions for production. This summer Hudson Valley's long hot sunny days and cool nights are ideal for growing conditions," said Chief Executive Officer, Tessa Edick of NYAcres. "With different Company divisions getting a traction and starting to show a real growth we finally decided to jump start our CBD division with an introduction of a new line of hemp products, that will include natural skin cosmetics, full spectrum tinctures and probiotic pet's edibles. Today we have all the right pieces in place together: a hemp farm run by professional farmers, experienced research and development team, led by Arkady Uryash, MD PhD, and strong goal-oriented sales and marketing team. The big role in our growth strategy will play online sales, where the Company will introduce its new online store but also a marketplace of CBD products from different manufactures, long awaited project, that only now can be a success with having on board a new team of professionals," said mCig Inc. Chief Executive Officer, Paul Rosenberg.

Subscribe Now! Watch us report LIVE

Follow us on Twitter for real time Financial News Updates:

Follow and talk to us on Instagram:

Facebook Like Us to receive live feeds:

About, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

Please Note is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the 'Site') is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Crop Infrastructure Corp. financial news dissemination and PR services, expects to be compensated five thousand dollars by the company. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: .

Media Contact: +1-877-601-1879



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store